Literature DB >> 6144558

Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding.

N Cook, A Richardson, D B Barnett.   

Abstract

The ability of the beta 1 partial agonists prenalterol and corwin , to displace the binding of [3H]dihydroalprenolol to the heterogeneous populations of beta-adrenoceptors on rat and rabbit lung membranes was compared. Both drugs exhibited higher affinity for the binding sites in rabbit lung (predominant beta 1) as compared to rat lung (predominant beta 2). Curve fitting analysis of the displacement curves into high affinity (beta 1) and low affinity (beta 2) components indicates that both drugs exhibit beta 1 selective affinity. Further competition experiments performed in the presence of carefully calculated concentrations of highly selective beta 1 (atenolol) or beta 2 (ICI 118,551) antagonists to produce homogeneous receptor subtype populations in rat and rabbit lung membranes respectively, confirmed this beta 1 selective affinity. These results suggest an approximate selective affinity ratio (beta 1 to beta 2) of ten and forty fold for prenalterol and corwin respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144558     DOI: 10.1016/0014-2999(84)90289-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Presynaptic beta 2-adrenoceptors on the sympathetic nerve fibres of the human saphenous vein: no evidence for involvement in adrenaline-mediated positive feedback loop regulating noradrenergic transmission.

Authors:  G Molderings; J Likungu; H R Zerkowski; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-04       Impact factor: 3.000

Review 2.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 3.  Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Authors:  D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

4.  Modulation of the autonomic control of the failing heart.

Authors:  H M Snow
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 5.  The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.

Authors:  H M Snow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

6.  Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs.

Authors:  N Galiè; M Metalli; R Zannoli; G Binetti; A Branzi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

Review 7.  Long-term studies with xamoterol in heart failure.

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Subendothelial beta 2-adrenoceptors in the rat vena cava: facilitation of noradrenaline release via local stimulation of angiotensin II synthesis.

Authors:  M Göthert; P Kollecker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-10       Impact factor: 3.000

9.  The influence of molecular structure on the affinity and efficacy of some beta-adrenoceptor agonists.

Authors:  P Molenaar; G A McPherson; E Malta; C Raper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

10.  The in vitro pharmacology of xamoterol (ICI 118,587).

Authors:  E Malta; M A Mian; C Raper
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.